Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986301 Monotherapy and Combination in Advanced Solid Cancers
NCT03956680Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of BMS-986301 in solid tumor (advanced stage) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Dose-Limiting Toxicities, Incidence of Adverse Events and 6 more. Started Mar 2019; status: completed.
02
Drugs
BMS-986301
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03956680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956680.